title: Immunotherapy in urothelial carcinoma: fade or future standard?
abstract: Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcinoma, might follow promising research on immunological targets.
authors: Department of Urology, Medical Center St. Josef, Regensburg University Medical Center, Regensburg, Germany.
authors: Johannes
authors: J
authors: Breyer
authors: Department of Urology, Medical Center St. Josef, Regensburg University Medical Center, Regensburg, Germany.
authors: Maximilian
authors: M
authors: Burger
authors: Department of Urology, Medical Center St. Josef, Regensburg University Medical Center, Regensburg, Germany; ; Urologische Praxis Dr. Raab, Abensberg, Germany.
authors: Wolfgang
authors: W
authors: Otto
keywords: Bacillus-Calmette-Guérin (BCG); Bladder; immunotherapy; urothelial carcinoma